ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 331

Gout Management in the Medical Community: A Claims-Based Analysis

N. Lawrence Edwards1, Naomi Schlesinger 2, Sanders Clark 3, Jeremy Paige 4, Theresa Arndt 4 and Peter Lipsky 5, 1Department of Medicine, University of Florida, Gainesville, FL, 2Division of Rheumatology, Department of Medicine, Rutgers, The State University of New Jersey, New Brunswick, NJ, 3HVH Precision Analytics, LLC, Wayne, PA, 4HVH Precision Analytics, Wayne, PA, 5AMPEL BioSolutions, LLC, Charlottesville, VA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: gout, tophaceous gout and urate

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 10, 2019

Session Title: Metabolic & Crystal Arthropathies Poster I: Clinical

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout is one of the most common inflammatory arthropathies. Despite available urate lowering therapies (ULT), many patients progress to chronic or advanced gout, characterized by the development of tophi, chronic inflammatory arthritis, and other manifestations resulting from persistent urate deposition. Although numerous guidelines exist for the management of gout, there is little information on the frequency of their implementation in the medical community.

The objective of this research was to evaluate the real-world practice patterns in patients diagnosed with gout using a large administrative claims database from the United States.

Methods: We carried out a retrospective analysis to identify patients with gout over an approximately 6-year period from October 2012 to August 2018. This study used data from the Symphony Integrated Dataverse, an administrative database covering over 250 million patients across the United States. Patients were identified as having gout if they were >18 years of age and had at least two medical claims for the diagnosis of gout on different days, separated by at least 3 months. Patients with acute gout were identified by ICD-10 code M10.*, chronic non-tophaceous gout (M1A.***0), tophaceous gout (M1A.***1) and uncontrolled gout (M10.*, M1A.*), the latter manifested by three gout codes (any) in the primary diagnosis position and three urate tests within the same calendar year. Percent and frequency of urate testing, rheumatology specialist visits, and prescriptions for ULT (allopurinol, febuxostat, probenecid, and lesinurad) were evaluated for each diagnostic group.

Results: We identified 1,162,747 gout patients (Table 1). The median age was 63 (range: 19-80), 74.1% were male, and the average duration of claims history in the database was 5.6 years. As shown in Figure 1, gout patients were seen most frequently by internists and family medicine practitioners. Patients with acute gout were infrequently see by rheumatologists, but the likelihood of encountering a rheumatologist progressively increased in subjects with advanced gout (chronic nontophaceous< tophaceous=uncontrolled). In all groups, the frequency of serum urate testing and receipt of a prescription for ULT significantly increased in gout patients seen by a rheumatologist (Table 2).

Conclusion: Most subjects with acute gout are not seen by a rheumatologist and less than half of those with advanced gout encounter a rheumatologist. However, measurement of serum urate and prescriptions for ULT are more frequent in those seen by a rheumatologist, but measurement of serum urate and prescriptions of ULT are not uniform. More frequent referral to rheumatologists and closer adherence to guidelines may improve outcomes for gout patients.

Table 1. Patient sample sizes, gout codes, and claims history in database

Figure 1. Frequency with which gout subsets are seen by various physicians

Table 2. Comparison of annual frequency of urate testing and urate lowering therapies in patients with or without a history of a rheumatology visit


Disclosure: N. Edwards, Astra Zeneca, 5, Horizon, 5, Ironwood Pharmaceuticals, 5, Selecta, 5; N. Schlesinger, amgen, 2, Astra Zeneca, 2, Horizon, 5, horizon, 5, IFM Therapeutics, 5, Mallinckrodt Pharmaceuticals, 5, Novartis, 5, olatec, 5, pfizer, 2, selecta, 5; S. Clark, None; J. Paige, None; T. Arndt, None; P. Lipsky, Horizon, 5, Janssen Research & Development, LLC, 2.

To cite this abstract in AMA style:

Edwards N, Schlesinger N, Clark S, Paige J, Arndt T, Lipsky P. Gout Management in the Medical Community: A Claims-Based Analysis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/gout-management-in-the-medical-community-a-claims-based-analysis/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gout-management-in-the-medical-community-a-claims-based-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.